Latest Content

The combination therapy met the primary OS end point vs durvalumab alone as first-line ES-SCLC maintenance therapy in the phase 3 DeLLphi-305 trial.

FDA approved zilganersen (ZANVASTRO), the first disease-modifying treatment for Alexander disease, based on pivotal trial data.

Despite positive data, the study authors call for prospective validation before PRO burden is incorporated into broader risk-stratification approaches.

Lung transplant candidates are aging rapidly, while cystic fibrosis decline in children shifts pediatric transplant toward sicker, more complex patients.

CMS awarded NY, RI, and MI Rural Health Transformation Program funding to expand rural health care workforce and technology access.

Cleveland heart failure experts discuss the new HFpEF pathway, CKM screening gaps, and drug access barriers.

COPD care gaps, financial strain, and sex disparities negatively impact patient outcomes and quality of life, according to the findings of 2 posters.

Exposure prevention, primary care capacity, and digital health equity all shape the future of respiratory disease care.

Tozorakimab dampened antiviral, allergic, and neutrophilic inflammation pathways in COPD airways, new phase 2a data show.